Skip to main content
Journal of Clinical Neurology (Seoul, Korea) logoLink to Journal of Clinical Neurology (Seoul, Korea)
. 2024 Aug 23;20(5):469–477. doi: 10.3988/jcn.2024.0176

Impact of Apolipoprotein E ε4 in Alzheimer’s Disease: A Meta-Analysis of Voxel-Based Morphometry Studies

Madison Bailey a,*, Zlatomira G Ilchovska b,c,*, Akram A Hosseini a,d,e, JeYoung Jung b,e,f,
PMCID: PMC11372214  PMID: 39227329

Abstract

Background and Purpose

Alzheimer’s disease (AD) is the most-prevalent form of dementia and imposes substantial burdens at the personal and societal levels. The apolipoprotein E (APOE) ε4 allele is a genetic factor known to increase AD risk and exacerbate brain atrophy and its symptoms. We aimed to provide a comprehensive review of the impacts of APOE ε4 on brain atrophy in AD as well as in mild cognitive impairment (MCI) as a transitional stage of AD.

Methods

We performed a coordinate-based meta-analysis of voxel-based morphometry studies to compare gray-matter atrophy patterns between carriers and noncarriers of APOE ε4. We obtained coordinate-based structural magnetic resonance imaging data from 1,135 individuals who met our inclusion criteria among 12 studies reported in PubMed and Google Scholar.

Results

We found that atrophy of the hippocampus and parahippocampus was significantly greater in APOE ε4 carriers than in noncarriers, especially among those with AD and MCI, while there was no significant atrophy in these regions in healthy controls who were also carriers.

Conclusions

The present meta-analysis has highlighted the significant link between the APOE ε4 allele and hippocampal atrophy in both AD and MCI, which emphasizes the critical influence of the allele on neurodegeneration, especially in the hippocampus. These findings improve the understanding of AD pathology, potentially facilitating progress in early detection, targeted interventions, and personalized care strategies for individuals at risk of AD who carry the APOE ε4 allele.

Keywords: Alzheimer’s disease, apolipoprotein, APOE, meta-analysis, voxel-based morphometry, mild cognitive impairment

Graphical Abstract

graphic file with name jcn-20-469-abf001.jpg

INTRODUCTION

Alzheimer’s disease (AD) is an increasing challenge to worldwide healthcare that imposes significant burdens at the individual, family, and societal levels.1 There are currently approximately 50 million patients with AD worldwide, with this prevalence being projected to double every 5 years and to reach 152 million by 2050.2 AD is the most-prevalent form of dementia and progresses slowly, but it inevitably induces substantial neuronal loss, especially in the medial temporal lobe and hippocampus,3 which manifests as memory decline, cognitive impairment, and changes in personality and language abilities.4,5 Although the underlying causes are complex and involve genetic, environmental, and lifestyle factors,6 the ε4 allele of the apolipoprotein E (APOE) gene has been identified as the strongest risk factor for AD.7 Approximately 60% of patients with AD carry an ε4 allele.7,8 Carrying one allele increases the AD risk two- to threefold, while those carrying two alleles face a 15-fold increased AD risk.9 The presence of the APOE ε4 allele can also influence the age at onset, progression rate, and severity of AD.10,11,12 The current study aimed to elucidate the impacts of the APOE ε4 allele on brain structure in AD through a comprehensive review of previous neuroimaging studies.

AD is characterized by amyloid plaques13 and neurofibrillary tangles14 that result in synaptic and neuronal loss, and brain atrophy.3 The progressive atrophy of the hippocampus and parahippocampal gyrus particularly disrupts this memory network in AD.15 The accumulation of neurofibrillary tangles and amyloid plaques are the primary pathological features of AD that contribute to decreased neuronal activity and synaptic functionality.16,17 Individuals carrying the APOE ε4 allele notably present with increased amyloid-β42 and tau protein concentrations, which are correlated with accelerated cognitive decline.18

The APOE gene located on chromosome 1919 is crucial to APOE synthesis, which plays a vital role in the transport of cholesterol and other lipids across cells in various body tissues.20 The APOE protein predominantly produced by astrocytes in the brain is critical for neuron maintenance and repair.21 This gene exists in three main isoforms (ε2, ε3, and ε4) that each have a unique impact on lipid metabolism and neuronal health.22 The ε4 variant is strongly associated with AD risk, playing a role in its progression by promoting amyloid β buildup and impairing the physiology of the medial temporal lobe.23 The association between the ε4 allele and elevated brain amyloid is evident in both the early,24,25 and advanced stages of AD.26,27 This genetic variant is also associated with a reduced hippocampal volume28 and more-significant memory deficits in patients with AD.29

Advances in neuroimaging, and particularly in magnetic resonance imaging, have been indispensable in identifying and quantifying brain atrophy in AD.30 Voxel-based morphometry (VBM) is a neuroimaging analysis technique that can identify focal differences in brain volume using statistical voxel-wise comparisons.31 Activation likelihood estimation (ALE) is a widely used algorithm for coordinate-based meta-analyses in neuroimaging.32 This involves assessing the convergence of activation points reported across different investigations by modeling these points as probability distributions. ALE treats reported activation foci as spatial probability distributions centered at specific coordinates. ALE maps are created by computing the union of activation probabilities for each voxel. The algorithm applies a permutation procedure to distinguish true convergence of foci from random clustering. Previous ALE meta-analyses of AD using VBM have focused on comparing AD patients with healthy controls (HCs), and have revealed atrophy of the hippocampus and parahippocampal gyrus.33,34,35 However, despite numerous previous studies on AD, there is a notable gap in research comparing brain atrophy between APOE ε4 carriers and noncarriers.

The present study aimed to fill this gap using ALE meta-analysis to synthesize data across studies, to provide a comprehensive understanding of the impact of the APOE ε4 allele on brain structure during various stages of cognitive decline. We compared brain atrophy between APOE ε4 carriers and noncarriers across AD, mild cognitive impairment (MCI), and HC groups. We applied ALE to data obtained in multiple studies to identify significant patterns of brain atrophy and thereby provide new insights into the relationship between the APOE ε4 allele and AD pathology.

METHODS

Literature search, selection criteria, and quality appraisal

We conducted a comprehensive literature search of PubMed and Google Scholar from October 2023 to February 2024 that aimed to find structural neuroimaging studies reported on in English and published at any time that compared APOE ε4 carriers with noncarriers. Our search strategy involved the following combinations of keywords: 1) (Alzheimer) AND (voxel-based morphometry or VBM) AND (apolipoprotein or APOE), and 2) (mild cognitive impairment or MCI) AND (voxel-based morphometry or VBM) AND (apolipoprotein or APOE). This search strategy yielded 83 studies, of which 12 were deemed to be relevant after applying the following inclusion criteria: 1) using VBM as the imaging modality; 2) using brain coordinates in a standardized stochastic space, either the Montreal Neurological Institute (MNI) or Talairach template; 3) comparing groups between APOE ε4 carriers and noncarriers; 4) investigating atrophy of gray matter; and 5) performing a whole-brain analysis. The initial screening process yielded 33 studies that were eligible for assessment, of which 21 were excluded for the following reasons: 1) comparative studies (n=6), 2) reviews (n=1), 3) case reports (n=1), 4) no genetic information (n=4), 5) no contrast information (n=2), 6) white-matter investigations (n=2), 7) no whole-brain analysis (n=2), or 8) nonhumans (n=3).

Fig. 1 illustrates the inclusion and exclusion criteria applied during the study selection process using a flow diagram based on the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 2020 for new systematic reviews.36 M.B., Z.I., and J.J. conducted all of the selection steps. The studies that met the criteria after the screening process were included in the meta-analysis.

Fig. 1. PRISMA flow diagram of the study selection process. AD, Alzheimer’s disease; HC, healthy control; MCI, mild cognitive impairment; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.

Fig. 1

ALE analysis

The impact of APOE ε4 status on brain atrophy was investigated comprehensively using a meta-analysis with the ALE algorithm in BrainMap GingerALE (version 3.0.2; https://brainmap.org).32 The experiments were categorized into AD, MCI, and HC groups (Table 1). Separate ALE meta-analyses were performed on four subexperiments: 1) with all patient experiments combined (AD+MCI), and 2) in each of the AD, MCI, and HC groups. Some studies included multiple experiments, and so the total number of experiments (n=25) exceeded the total number of studies (n=12). All Talairach coordinates were transformed into MNI space using the transform called icbm2tal developed by Laird et al.37 The probability criterion was set as an uncorrected p value of <0.001 with 1,000 permutations. We reported significant clusters with a corrected p value of <0.05 for the false discovery rate (FDR) with the minimum cluster volume set to 200 mm3.

Table 1. The 12 studies included in the meta-analysis.

Study Condition Participants
Chang et al.,58 2019 AD APOE ε4 carriers=38, noncarriers=59
Forno et al.,59 2023 AD APOE ε4 carriers=51, noncarriers=36
Brys et al.,57 2009 MCI APOE ε4 carriers=13, noncarriers=11
Novellino et al.,66 2019 MCI APOE ε4 carriers=40, noncarriers=55
You et al.,67 2021 MCI APOE ε4 carriers=22, noncarriers=38
Alexander et al.,56 2012 HC APOE ε4 carriers=14, noncarriers=10
Goltermann et al.,60 2019 HC APOE ε4 carriers=22, noncarriers=38
Honea et al.,62 2009 HC APOE ε4 carriers=14, noncarriers=39
Honea et al.,63 2009 HC APOE ε4 carriers=34, noncarriers=29
Honea et al.,61 2010 HC APOE ε4 carriers=14, noncarriers=39
Nao et al.,65 2017 HC APOE ε4 carriers=22, noncarriers=38
Mosconi et al.,64 2014 HC APOE ε4 carriers=19, noncarriers=33

AD, Alzheimer’s disease; APOE, apolipoprotein E; HC, healthy control; MCI, mild cognitive impairment.

NeuroSynth

NeuroSynth38 (http://neurosynth.org) was employed to connect focal brain atrophy identified in the VBM meta-analysis with associated functional systems and related cognitive functions. This approach treats the brain as an interconnected network in which structural damage in one region can affect related functional systems.39 By combining these analyses we aimed to obtain a more-comprehensive understanding of the interplay between brain structure and function in patients with AD carrying APOE ε4. We selected the peak coordinates from each cluster identified in our meta-analysis as a seed region to create meta-analytic coactivation maps and to identify keywords related to these maps. NeuroSynth generates a z-score map that indicates the probability that a specific term was identified in a research article in association with an activation site. We applied a voxelwise threshold to the NeuroSynth outcomes at a significance level of 0.01 while adjusting for the FDR. Up to five keywords with z-scores >0 were selected.

RESULTS

ALE meta-analysis

Twelve studies involving 25 experiments with 1,135 participants and yielding 164 foci met the relevant inclusion criteria and were included in the analysis. The results are summarized in Fig. 2 and Table 2. The primary analysis with all patients (AD+MCI; 10 experiments, 51 foci, and 608 patients) revealed that patients carrying the APOE ε4 allele exhibited significant atrophy of the bilateral hippocampus and parahippocampal regions relative to noncarriers (Fig. 2A). Further detailed analyses by patient category revealed that in patients with AD (6 experiments, 35 foci, and 405 ADs), APOE ε4 carriers exhibited notable atrophy of the bilateral hippocampus, the right parahippocampal gyrus, and the posterior cingulate cortex (PCC) (Fig. 2B). In patients with MCI (4 experiments, 16 foci, and 203 MCIs), carriers of the APOE ε4 allele exhibited atrophy of the bilateral parahippocampal gyrus and the globus pallidus (Fig. 2C). Among HCs (15 experiments, 113 foci, and 527 HCs), those carrying the APOE ε4 allele exhibited atrophy of the right superior temporal gyrus (Fig. 2D).

Fig. 2. Results of the ALE meta-analysis: all patients (AD+MCI) carriers<noncarriers (A), AD carriers<noncarriers (B), MCI carriers<noncarriers (C), and HC carriers<noncarriers (D). Color bar indicates z-scores. AD, Alzheimer’s disease; ALE, activation likelihood estimation; HC, healthy control; MCI, mild cognitive impairment.

Fig. 2

Table 2. Results of the ALE meta-analysis of APOE carriers<noncarriers.

Cluster Coordinates (x, y, z) ALE score z p
All (AD+MCI) carriers<noncarriers
Parahippocampal gyrus 28, -34, -2 0.034 7.362 <0.000001
Hippocampus -26, -14, -18 0.015 4.448 0.000004
Parahippocampal gyrus 26, -14, -20 0.017 4.776 0.000001
Hippocampus 32, -22, -10 0.018 5.176 <0.000001
AD carriers<noncarriers
Parahippocampal gyrus 26, -34, -2 0.027 6.667 <0.000001
Hippocampus 32, -22, -10 0.018 5.309 <0.000001
Posterior cingulate cortex -8, -52, 26 0.018 5.279 <0.000001
Hippocampus -26, -39, -2 0.018 5.296 <0.000001
MCI carriers<noncarriers
Parahippocampal gyrus -24, -14, -18 0.014 4.855 0.000001
Globus pallidus -18, -8, -12 0.011 4.463 0.000004
Parahippocampal gyrus 26, -14, -18 0.020 6.185 <0.000001
Parahippocampal gyrus 26, -34, -2 0.015 4.966 <0.000001
HC carriers<noncarriers
Superior temporal gyrus 54, -30, 8 0.025 5.655 <0.000001
Middle temporal gyrus 56, -34, 2 0.019 4.840 0.000001

AD, Alzheimer’s disease; ALE, activation likelihood estimation; APOE, apolipoprotein E; HC, healthy control; MCI, mild cognitive impairment.

NeuroSynth

To identify the functional networks underlying the patterns observed in our meta-analysis, specifically comparing AD carriers and noncarriers, we utilized NeuroSynth to perform a meta-analytic coactivation analysis. The results are summarized in Fig. 3. Analysis of the coactivation map for the parahippocampal gyrus cluster (MNI coordinates: 26, −34, −2) revealed connectivity with the bilateral hippocampus, parahippocampal gyrus, and PCC (Fig. 3A). The hippocampal clusters (MNI coordinates: 32, −22, −10 and −26, −39, −2) were primarily linked with the bilateral hippocampus (Fig. 3B and C). The coactivation analysis showed that the PCC cluster (MNI coordinate: −8, −52, 26) was associated with the medial prefrontal cortex, precuneus, PCC, bilateral angular gyrus, middle temporal gyrus, and hippocampus (Fig. 3D). Additionally, word clouds generated by NeuroSynth meta-analysis decoding revealed that the most frequently associated terms with the brain activity patterns in these coactivation maps included “episodic,” “memory,” “encoding,” and “retrieval” (Fig. 3E).

Fig. 3. NeuroSynth results. Meta-analytic coactivation maps of the parahippocampal gyrus cluster (A), right hippocampus cluster (B), left hippocampus cluster (C), and PCC cluster (D). Word cloud illustrating the findings of a NeuroSynth meta-analysis revealing the terms most commonly associated with the brain activity patterns of seed regions identified when comparing AD carriers and noncarriers (E). Color bar indicates z-scores. AD, Alzheimer’s disease; MNI, Montreal Neurological Institute; PCC, posterior cingulate cortex.

Fig. 3

DISCUSSION

The present meta-analysis aimed to determine how the APOE ε4 allele influences brain atrophy in AD, in order to obtain insights into the mechanisms underpinning brain atrophy in this condition. Our examinations of the effects of the APOE ε4 allele in individuals at various stages of clinical progression of AD and MCI have revealed how this allele impacts the hippocampus and parahippocampus, which are areas vulnerable to neurodegenerative changes. We found significantly more atrophy of the hippocampus and parahippocampus in APOE ε4 carriers than in noncarriers, especially within the AD and MCI groups, while HC carriers showed no significant atrophy in these regions. These findings are consistent with previous research highlighting the susceptibility of the hippocampus to early degenerative changes in AD, in which it plays a critical role in memory formation, storage, and retrieval.3,33,34,35 The observed atrophy in these critical memory regions among APOE ε4 carriers suggests that the allele contributes to the exacerbation of memory loss in AD, supporting the notion that this genetic variant is a significant risk factor for accelerated neurodegeneration.7,8,40

The presence of the APOE ε4 allele has been associated with a reduced hippocampal volume, which is particularly evident in older individuals with AD and MCI, with an average volume decrease of about 4% in the hippocampus per APOE ε4 allele.41,42,43 Based on findings from large-scale genome-wide association study meta-analyses, Lupton et al.44 further confirmed the link between the APOE ε4 allele and hippocampal volume reduction in patients with AD and MCI, indicating that the hippocampus is smaller in carriers of the ε4 allele than in noncarriers. Moreover, Kerchner et al.45 reported that patients with MCI and AD who were also APOE ε4 carriers had thinner hippocampal subregions and showed worse episodic memory abilities relative to noncarriers. Moreover, our analyses using NeuroSynth revealed the hippocampal network that is associated with memory function. Located in the medial temporal lobe, the hippocampus is among the first regions to be damaged in AD.3 This early vulnerability is attributable to the critical roles that this brain structure plays in encoding new memories and navigating spatial environments.46 The parahippocampal gyrus, which surrounds the hippocampus, supports memory encoding and retrieval by processing environmental contextual information.47 Together these structures are crucial components of the brain’s memory network that facilitate the transition of short-term memories to long-term storage.48 Our meta-analysis corroborated these genomic and neuroimaging findings, demonstrating the significant influence of the APOE ε4 allele on hippocampal atrophy in AD and the related memory impairments.

Furthermore, our analysis revealed atrophy of the PCC among patients with AD that was greater in those carrying the APOE ε4 allele than in noncarriers. The PCC is an integral part of the Papez circuit, which also includes the hippocampus, mammillary bodies, thalamus, and parahippocampal gyrus.49 This circuit plays pivotal roles in memory formation and emotional regulation, and is implicated in the deterioration of episodic memory and spatial navigation ability seen in AD.50 The PCC is also a central element of the default-mode network, which is known to be affected by AD pathology.51,52 Studies have repeatedly found that the volume of the PCC52 and its functional connectivity51 are disrupted in AD. Importantly, both AD and MCI patients who carry the APOE ε4 allele have been observed to exhibit loss of gray matter53 and impaired functional connectivity54 in the PCC. Consistent with previously obtained evidence, our findings suggest the influence of the APOE ε4 allele on PCC abnormalities, supporting the notion of PCC atrophy as a distinctive cortical feature of AD.55 Overall our results highlight the contribution of the APOE ε4 allele to the genetic risk of brain atrophy and the cognitive deficits associated with AD.

Despite the robust associations observed, caution is required when interpreting the results of this study due to its limitations, which include a relatively small sample due to the scarcity of studies directly comparing APOE ε4 carriers with noncarriers. This study did not have a mechanistic design, and so further studies are needed to better understand whether the APOE ε4 allele has a direct or indirect impact on AD pathology, focal brain atrophy/neurodegeneration, or conversion of MCI to AD, or on disease progression. However, our analyses provide a foundational basis for future research in this field, suggesting the importance of genetic screening in tailoring potential prevention and treatment strategies for AD. APOE genetic testing is important for monitoring amyloid therapies such as those using donanemab and lecanemab, and it could also be useful for investigating whether amyloid therapy can slow down the hippocampal atrophy in carriers vs. noncarriers. Recognizing the multifactorial nature of AD, further studies are also essential to unravel the complex interplay of genetic and neuronal factors underlying the disease, in order to facilitate the development of more-effective interventions and a deeper understanding of its pathophysiology.

By applying a meta-analysis to structural neuroimaging data, we have demonstrated how this genetic variant contributes to the understanding of disease and its impact on brain structure. By identifying specific brain atrophy patterns associated with the APOE ε4 allele, our meta-analysis revealed the significant link between genetic factors and neurodegeneration, and hence potential pathways for targeted interventions and treatments. The recognition that APOE ε4 carriers in AD exhibit distinct patterns of brain atrophy, especially in the hippocampus and parahippocampus, will enable more-accurate risk assessments and individualized approaches to mitigating neurodegenerative progression.

Footnotes

Author Contributions:
  • Conceptualization: JeYoung Jung.
  • Formal analysis: Madison Bailey, Zlatomira G. Ilchovska, JeYoung Jung.
  • Funding acquisition: Akram A. Hosseini, JeYoung Jung.
  • Investigation: Madison Bailey, Zlatomira G. Ilchovska, JeYoung Jung.
  • Methodology: Madison Bailey, Zlatomira G. Ilchovska, JeYoung Jung.
  • Supervision: Akram A. Hosseini, JeYoung Jung.
  • Visualization: Madison Bailey, Zlatomira G. Ilchovska, JeYoung Jung.
  • Writing—original draft: Madison Bailey, Zlatomira G. Ilchovska, JeYoung Jung.
  • Writing—review & editing: Akram A. Hosseini, JeYoung Jung.

Conflicts of Interest: The authors have no potential conflicts of interest to disclose.

Funding Statement: This research was supported by AMS Springboard (SBF007\100077) to JJ. AAH has received funding from the Medical Research Council, UK (Grant MR/T005580/1) and the National Institute of Health/NIA, USA (Grant 1R56AG074467-01). She has received honoraria from Biogen, Eisai, and Lilly for advisory consultations and teaching related to Alzheimer’s disease.

Availability of Data and Material

All data generated or analyzed during the study are included in this published article.

References

  • 1.Lanctôt KL, Hviid Hahn-Pedersen J, Eichinger CS, Freeman C, Clark A, Tarazona LRS, et al. Burden of illness in people with Alzheimer’s disease: a systematic review of epidemiology, comorbidities and mortality. J Prev Alzheimers Dis. 2024;11:97–107. doi: 10.14283/jpad.2023.61. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.2022 Alzheimer’s disease facts and figures. Alzheimers Dement. 2022;18:700–789. doi: 10.1002/alz.12638. [DOI] [PubMed] [Google Scholar]
  • 3.Pini L, Pievani M, Bocchetta M, Altomare D, Bosco P, Cavedo E, et al. Brain atrophy in Alzheimer’s disease and aging. Ageing Res Rev. 2016;30:25–48. doi: 10.1016/j.arr.2016.01.002. [DOI] [PubMed] [Google Scholar]
  • 4.Jahn H. Memory loss in Alzheimer’s disease. Dialogues Clin Neurosci. 2013;15:445–454. doi: 10.31887/DCNS.2013.15.4/hjahn. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Corey-Bloom J. The ABC of Alzheimer’s disease: cognitive changes and their management in Alzheimer’s disease and related dementias. Int Psychogeriatr. 2002;14(Suppl 1):51–75. doi: 10.1017/s1041610203008664. [DOI] [PubMed] [Google Scholar]
  • 6.Eid A, Mhatre I, Richardson JR. Gene-environment interactions in Alzheimer’s disease: a potential path to precision medicine. Pharmacol Ther. 2019;199:173–187. doi: 10.1016/j.pharmthera.2019.03.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013;9:106–118. doi: 10.1038/nrneurol.2012.263. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science. 1993;261:921–923. doi: 10.1126/science.8346443. [DOI] [PubMed] [Google Scholar]
  • 9.Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. JAMA. 1997;278:1349–1356. [PubMed] [Google Scholar]
  • 10.Corder EH, Basun H, Lannfelt L, Viitanen M, Winblad B. Attenuation of apolipoprotein E epsilon4 allele gene dose in late age. Lancet. 1996;347:542. doi: 10.1016/s0140-6736(96)91173-3. [DOI] [PubMed] [Google Scholar]
  • 11.Frisoni GB, Govoni S, Geroldi C, Bianchetti A, Calabresi L, Franceschini G, et al. Gene dose of the epsilon 4 allele of apolipoprotein E and disease progression in sporadic late-onset Alzheimer’s disease. Ann Neurol. 1995;37:596–604. doi: 10.1002/ana.410370509. [DOI] [PubMed] [Google Scholar]
  • 12.Cosentino FI, Bosco P, Drago V, Prestianni G, Lanuzza B, Iero I, et al. The APOE epsilon4 allele increases the risk of impaired spatial working memory in obstructive sleep apnea. Sleep Med. 2008;9:831–839. doi: 10.1016/j.sleep.2007.10.015. [DOI] [PubMed] [Google Scholar]
  • 13.Li K, Qu H, Ma M, Xia C, Cai M, Han F, et al. Correlation between brain structure atrophy and plasma amyloid-β and phosphorylated Tau in patients with Alzheimer’s disease and amnestic mild cognitive impairment explored by surface-based morphometry. Front Aging Neurosci. 2022;14:816043. doi: 10.3389/fnagi.2022.816043. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Goedert M, Sisodia SS, Price DL. Neurofibrillary tangles and beta-amyloid deposits in Alzheimer’s disease. Curr Opin Neurobiol. 1991;1:441–447. doi: 10.1016/0959-4388(91)90067-h. [DOI] [PubMed] [Google Scholar]
  • 15.Rao YL, Ganaraja B, Murlimanju BV, Joy T, Krishnamurthy A, Agrawal A. Hippocampus and its involvement in Alzheimer’s disease: a review. 3 Biotec. 2022;12:55. doi: 10.1007/s13205-022-03123-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Chu LW. Alzheimer’s disease: early diagnosis and treatment. Hong Kong Med J. 2012;18:228–237. [PubMed] [Google Scholar]
  • 17.Josephs KA, Dickson DW, Tosakulwong N, Weigand SD, Murray ME, Petrucelli L, et al. Rates of hippocampal atrophy and presence of post-mortem TDP-43 in patients with Alzheimer’s disease: a longitudinal retrospective study. Lancet Neurol. 2017;16:917–924. doi: 10.1016/S1474-4422(17)30284-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Benson GS, Bauer C, Hausner L, Couturier S, Lewczuk P, Peters O, et al. Don’t forget about tau: the effects of ApoE4 genotype on Alzheimer’s disease cerebrospinal fluid biomarkers in subjects with mild cognitive impairment-data from the dementia competence network. J Neural Transm (Vienna) 2022;129:477–486. doi: 10.1007/s00702-022-02461-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Moreno-Grau S, Hernández I, Heilmann-Heimbach S, Ruiz S, Rosende-Roca M, Mauleón A, et al. Genome-wide significant risk factors on chromosome 19 and the APOE locus. Oncotarget. 2018;9:24590–24600. doi: 10.18632/oncotarget.25083. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988;240:622–630. doi: 10.1126/science.3283935. [DOI] [PubMed] [Google Scholar]
  • 21.Husain MA, Laurent B, Plourde M. APOE and Alzheimer’s disease: from lipid transport to physiopathology and therapeutics. Front Neurosci. 2021;15:630502. doi: 10.3389/fnins.2021.630502. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Phillips MC. Apolipoprotein E isoforms and lipoprotein metabolism. IUBMB Life. 2014;66:616–623. doi: 10.1002/iub.1314. [DOI] [PubMed] [Google Scholar]
  • 23.Di Battista AM, Heinsinger NM, Rebeck GW. Alzheimer’s disease genetic risk factor APOE-ε4 also affects normal brain function. Curr Alzheimer Res. 2016;13:1200–1207. doi: 10.2174/1567205013666160401115127. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Caselli RJ, Dueck AC, Osborne D, Sabbagh MN, Connor DJ, Ahern GL, et al. Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. N Engl J Med. 2009;361:255–263. doi: 10.1056/NEJMoa0809437. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol. 2013;12:357–367. doi: 10.1016/S1474-4422(13)70044-9. [DOI] [PubMed] [Google Scholar]
  • 26.Nelson PT, Pious NM, Jicha GA, Wilcock DM, Fardo DW, Estus S, et al. APOE-ε2 and APOE-ε4 correlate with increased amyloid accumulation in cerebral vasculature. J Neuropathol Exp Neurol. 2013;72:708–715. doi: 10.1097/NEN.0b013e31829a25b9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Tai LM, Bilousova T, Jungbauer L, Roeske SK, Youmans KL, Yu C, et al. Levels of soluble apolipoprotein E/amyloid-β (Aβ) complex are reduced and oligomeric Aβ increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples. J Biol Chem. 2013;288:5914–5926. doi: 10.1074/jbc.M112.442103. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Manning EN, Barnes J, Cash DM, Bartlett JW, Leung KK, Ourselin S, et al. APOE ε4 is associated with disproportionate progressive hippocampal atrophy in AD. PLoS One. 2014;9:e97608. doi: 10.1371/journal.pone.0097608. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Wolk DA, Dickerson BC Alzheimer’s Disease Neuroimaging Initiative. Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer’s disease. Proc Natl Acad Sci U S A. 2010;107:10256–10261. doi: 10.1073/pnas.1001412107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Dona O, Thompson J, Druchok C. Comprehensive review on magnetic resonance imaging in Alzheimer’s disease. Crit Rev Biomed Eng. 2016;44:213–225. doi: 10.1615/CritRevBiomedEng.2016019544. [DOI] [PubMed] [Google Scholar]
  • 31.Ashburner J, Friston KJ. Voxel-based morphometry--the methods. Neuroimage. 2000;11(6 Pt 1):805–821. doi: 10.1006/nimg.2000.0582. [DOI] [PubMed] [Google Scholar]
  • 32.Eickhoff SB, Laird AR, Grefkes C, Wang LE, Zilles K, Fox PT. Coordinate-based activation likelihood estimation meta-analysis of neuroimaging data: a random-effects approach based on empirical estimates of spatial uncertainty. Hum Brain Mapp. 2009;30:2907–2926. doi: 10.1002/hbm.20718. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Li J, Pan P, Huang R, Shang H. A meta-analysis of voxel-based morphometry studies of white matter volume alterations in Alzheimer’s disease. Neurosci Biobehav Rev. 2012;36:757–763. doi: 10.1016/j.neubiorev.2011.12.001. [DOI] [PubMed] [Google Scholar]
  • 34.Ferreira LK, Diniz BS, Forlenza OV, Busatto GF, Zanetti MV. Neurostructural predictors of Alzheimer’s disease: a meta-analysis of VBM studies. Neurobiol Aging. 2011;32:1733–1741. doi: 10.1016/j.neurobiolaging.2009.11.008. [DOI] [PubMed] [Google Scholar]
  • 35.Wang WY, Yu JT, Liu Y, Yin RH, Wang HF, Wang J, et al. Voxel-based meta-analysis of grey matter changes in Alzheimer’s disease. Transl Neurodegener. 2015;4:6. doi: 10.1186/s40035-015-0027-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Laird AR, Robinson JL, McMillan KM, Tordesillas-Gutiérrez D, Moran ST, Gonzales SM, et al. Comparison of the disparity between Talairach and MNI coordinates in functional neuroimaging data: validation of the Lancaster transform. Neuroimage. 2010;51:677–683. doi: 10.1016/j.neuroimage.2010.02.048. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Yarkoni T, Poldrack RA, Nichols TE, Van Essen DC, Wager TD. Large-scale automated synthesis of human functional neuroimaging data. Nat Methods. 2011;8:665–670. doi: 10.1038/nmeth.1635. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Aerts H, Fias W, Caeyenberghs K, Marinazzo D. Brain networks under attack: robustness properties and the impact of lesions. Brain. 2016;139(Pt 12):3063–3083. doi: 10.1093/brain/aww194. [DOI] [PubMed] [Google Scholar]
  • 40.Lancaster TM, Hill MJ, Sims R, Williams J. Microglia – mediated immunity partly contributes to the genetic association between Alzheimer’s disease and hippocampal volume. Brain Behav Immun. 2019;79:267–273. doi: 10.1016/j.bbi.2019.02.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Chauhan G, Adams HHH, Bis JC, Weinstein G, Yu L, Töglhofer AM, et al. Association of Alzheimer’s disease GWAS loci with MRI markers of brain aging. Neurobiol Aging. 2015;36:1765.e7–1765.e16. doi: 10.1016/j.neurobiolaging.2014.12.028. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Fleisher A, Grundman M, Jack CR, Jr, Petersen RC, Taylor C, Kim HT, et al. Sex, apolipoprotein E epsilon 4 status, and hippocampal volume in mild cognitive impairment. Arch Neurol. 2005;62:953–957. doi: 10.1001/archneur.62.6.953. [DOI] [PubMed] [Google Scholar]
  • 43.Fleisher AS, Chen K, Liu X, Ayutyanont N, Roontiva A, Thiyyagura P, et al. Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease. Neurobiol Aging. 2013;34:1–12. doi: 10.1016/j.neurobiolaging.2012.04.017. [DOI] [PubMed] [Google Scholar]
  • 44.Lupton MK, Strike L, Hansell NK, Wen W, Mather KA, Armstrong NJ, et al. The effect of increased genetic risk for Alzheimer’s disease on hippocampal and amygdala volume. Neurobiol Aging. 2016;40:68–77. doi: 10.1016/j.neurobiolaging.2015.12.023. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Kerchner GA, Berdnik D, Shen JC, Bernstein JD, Fenesy MC, Deutsch GK, et al. APOE ε4 worsens hippocampal CA1 apical neuropil atrophy and episodic memory. Neurology. 2014;82:691–697. doi: 10.1212/WNL.0000000000000154. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Bird CM, Burgess N. The hippocampus and memory: insights from spatial processing. Nat Rev Neurosci. 2008;9:182–194. doi: 10.1038/nrn2335. [DOI] [PubMed] [Google Scholar]
  • 47.Aminoff EM, Kveraga K, Bar M. The role of the parahippocampal cortex in cognition. Trends Cogn Sci. 2013;17:379–390. doi: 10.1016/j.tics.2013.06.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.van Strien NM, Cappaert NL, Witter MP. The anatomy of memory: an interactive overview of the parahippocampal-hippocampal network. Nat Rev Neurosci. 2009;10:272–282. doi: 10.1038/nrn2614. [DOI] [PubMed] [Google Scholar]
  • 49.Aggleton JP, Nelson AJD, O’Mara SM. Time to retire the serial Papez circuit: implications for space, memory, and attention. Neurosci Biobehav Rev. 2022;140:104813. doi: 10.1016/j.neubiorev.2022.104813. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Forno G, Lladó A, Hornberger M. Going round in circles—the Papez circuit in Alzheimer’s disease. Eur J Neurosci. 2021;54:7668–7687. doi: 10.1111/ejn.15494. [DOI] [PubMed] [Google Scholar]
  • 51.Buckner RL, Andrews-Hanna JR, Schacter DL. The brain’s default network: anatomy, function, and relevance to disease. Ann N Y Acad Sci. 2008;1124:1–38. doi: 10.1196/annals.1440.011. [DOI] [PubMed] [Google Scholar]
  • 52.Callen DJ, Black SE, Gao F, Caldwell CB, Szalai JP. Beyond the hippocampus: MRI volumetry confirms widespread limbic atrophy in AD. Neurology. 2001;57:1669–1674. doi: 10.1212/wnl.57.9.1669. [DOI] [PubMed] [Google Scholar]
  • 53.Haller S, Montandon ML, Rodriguez C, Ackermann M, Herrmann FR, Giannakopoulos P. APOE*E4 is associated with gray matter loss in the posterior cingulate cortex in healthy elderly controls subsequently developing subtle cognitive decline. AJNR Am J Neuroradiol. 2017;38:1335–1342. doi: 10.3174/ajnr.A5184. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Sheline YI, Morris JC, Snyder AZ, Price JL, Yan Z, D’Angelo G, et al. APOE4 allele disrupts resting state fMRI connectivity in the absence of amyloid plaques or decreased CSF Aβ42. J Neurosci. 2010;30:17035–17040. doi: 10.1523/JNEUROSCI.3987-10.2010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Dickerson BC, Bakkour A, Salat DH, Feczko E, Pacheco J, Greve DN, et al. The cortical signature of Alzheimer’s disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex. 2009;19:497–510. doi: 10.1093/cercor/bhn113. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Alexander GE, Bergfield KL, Chen K, Reiman EM, Hanson KD, Lin L, et al. Gray matter network associated with risk for Alzheimer’s disease in young to middle-aged adults. Neurobiol Aging. 2012;33:2723–2732. doi: 10.1016/j.neurobiolaging.2012.01.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Brys M, Glodzik L, Mosconi L, Switalski R, De Santi S, Pirraglia E, et al. Magnetic resonance imaging improves cerebrospinal fluid biomarkers in the early detection of Alzheimer’s disease. J Alzheimers Dis. 2009;16:351–362. doi: 10.3233/JAD-2009-0968. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Chang YT, Kazui H, Ikeda M, Huang CW, Huang SH, Hsu SW, et al. Genetic interaction of APOE and FGF1 is associated with memory impairment and hippocampal atrophy in Alzheimer’s disease. Aging Dis. 2019;10:510–519. doi: 10.14336/AD.2018.0606. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Forno G, Contador J, Pérez-Millan A, Guillen N, Falgàs N, Sarto J, et al. The APOE4 effect: structural brain differences in Alzheimer’s disease according to the age at symptom onset. Eur J Neurol. 2023;30:597–605. doi: 10.1111/ene.15657. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Goltermann J, Redlich R, Dohm K, Zaremba D, Repple J, Kaehler C, et al. Apolipoprotein E homozygous ε4 allele status: a deteriorating effect on visuospatial working memory and global brain structure. Front Neurol. 2019;10:552. doi: 10.3389/fneur.2019.00552. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Honea RA, Swerdlow RH, Vidoni ED, Goodwin J, Burns JM. Reduced gray matter volume in normal adults with a maternal family history of Alzheimer disease. Neurology. 2010;74:113–120. doi: 10.1212/WNL.0b013e3181c918cb. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Honea RA, Thomas GP, Harsha A, Anderson HS, Donnelly JE, Brooks WM, et al. Cardiorespiratory fitness and preserved medial temporal lobe volume in Alzheimer disease. Alzheimer Dis Assoc Disord. 2009;23:188–197. doi: 10.1097/WAD.0b013e31819cb8a2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Honea RA, Vidoni E, Harsha A, Burns JM. Impact of APOE on the healthy aging brain: a voxel-based MRI and DTI study. J Alzheimers Dis. 2009;18:553–564. doi: 10.3233/JAD-2009-1163. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Mosconi L, Murray J, Tsui WH, Li Y, Spector N, Goldowsky A, et al. Brain imaging of cognitively normal individuals with 2 parents affected by late-onset AD. Neurology. 2014;82:752–760. doi: 10.1212/WNL.0000000000000181. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Nao J, Sun H, Wang Q, Ma S, Zhang S, Dong X, et al. Adverse effects of the apolipoprotein E ε4 allele on episodic memory, task switching and gray matter volume in healthy young adults. Front Hum Neurosci. 2017;11:346. doi: 10.3389/fnhum.2017.00346. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Novellino F, López ME, Vaccaro MG, Miguel Y, Delgado ML, Maestu F. Association between hippocampus, thalamus, and caudate in mild cognitive impairment APOEε4 carriers: a structural covariance MRI study. Front Neurol. 2019;10:1303. doi: 10.3389/fneur.2019.01303. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.You M, Zhou X, Yin W, Wan K, Zhang W, Li C, et al. The influence of MTHFR polymorphism on gray matter volume in patients with amnestic mild cognitive impairment. Front Neurosci. 2021;15:778123. doi: 10.3389/fnins.2021.778123. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

All data generated or analyzed during the study are included in this published article.


Articles from Journal of Clinical Neurology (Seoul, Korea) are provided here courtesy of Korean Neurological Association

RESOURCES